Modality
ERT
MOA
CAR-T CD19
Target
C5
Pathway
Apoptosis
Parkinson's
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
Dec 2019
→ Sep 2028
Phase 1Current
NCT08299222
1,965 pts·Parkinson's
2020-09→2028-09·Completed
NCT07928113
2,363 pts·Parkinson's
2019-12→2028-04·Not yet recruiting
4,328 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-04-122.0y awayInterim· Parkinson's
2028-09-152.5y awayInterim· Parkinson's
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Not yet…
P1
Complet…
Catalysts
Interim
2028-04-12 · 2.0y away
Parkinson's
Interim
2028-09-15 · 2.5y away
Parkinson's
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08299222 | Phase 1 | Parkinson's | Completed | 1965 | OS |
| NCT07928113 | Phase 1 | Parkinson's | Not yet recr... | 2363 | EASI-75 |
Competitors (10)